Quest Diagnostics stock hits all-time high of $180.11

Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services with a market capitalization of nearly $20 billion, has reached an all-time high, with its stock price soaring to $180.11. According to InvestingPro analysis, the stock currently appears to be trading above its Fair Value. This milestone reflects a significant uptrend in the company’s market performance, marking a remarkable 52-week journey. Over the past year, Quest Diagnostics has seen an impressive 31.86% total return, while maintaining a notably low price volatility. The company has demonstrated its commitment to shareholder value by maintaining dividend payments for 22 consecutive years, with a current yield of 1.79%. InvestingPro subscribers can access 8 additional key insights about DGX’s performance and prospects. The all-time high represents not just a peak in share price but also the culmination of a year of strong financial results and strategic expansions that have resonated well with the market. Trading at a P/E ratio of 22.24, with analyst targets reaching up to $200 per share, the company maintains a "GOOD" overall financial health score according to InvestingPro’s comprehensive analysis, available in the detailed Pro Research Report.

In other recent news, Quest Diagnostics reported its Q1 2025 earnings, exceeding market expectations with an adjusted earnings per share (EPS) of $2.21, compared to the forecasted $2.16. The company’s revenue reached $2.65 billion, slightly surpassing the anticipated $2.64 billion, marking a 12.1% year-over-year growth. Fitch Ratings upgraded Quest Diagnostics’ Long-Term Issuer Default Rating to ’BBB+’ with a stable outlook, citing strong operational performance and consistent growth. Additionally, JPMorgan raised its price target for Quest Diagnostics from $180 to $190, maintaining a Neutral stock rating, and adjusted its EPS forecasts for 2025 and 2026. Quest Diagnostics’ shareholders recently elected directors and approved executive compensation at the 2025 Annual Meeting. The appointment of PricewaterhouseCoopers as the independent auditor for 2025 was also ratified. A stockholder proposal regarding the ability to call a special meeting was not approved. These developments reflect ongoing confidence in Quest Diagnostics’ strategic direction and financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.